Soft Tissue Sarcoma Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Philogen, Gradalis, Epizyme, CytRx, KaryoPharm, Nanobiotix, Apexigen, Lytix, Incyte, Iovance

Soft Tissue Sarcoma Market: Breakthrough Forecast Study Predicts Astounding Growth in the Upcoming Years | Philogen, Gradalis, Epizyme, CytRx, KaryoPharm, Nanobiotix, Apexigen, Lytix, Incyte, Iovance
Delveinsight Business Research LLP
As per DelveInsight, the Soft Tissue Sarcoma Market is anticipated to evolve immensely in the coming years owing to the extensive research and development activities of pharmaceutical companies, along with the launch of various therapies, and the rise in the number of cases of Soft Tissue Sarcoma. The number of clinical trials for Soft Tissue Sarcoma is increasing, and their success rate also holds the potential for commercial approval during the forecast period.

DelveInsight’s “Soft Tissue Sarcoma Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Soft Tissue Sarcoma market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Soft Tissue Sarcoma drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Soft Tissue Sarcoma treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Soft Tissue Sarcoma: An Overview

Soft tissue sarcoma (STS) is a broad term for cancers that start in soft tissues (muscle, tendons, fat, lymph and blood vessels, and nerves). STS are a rare and heterogeneous group of tumors, arising in connective tissues embryologically derived from the mesenchyme. Soft tissue sarcomas (STSs) comprise 80 entities defined by the World Health Organization (WHO) classification based on a combination of distinctive morphological, immunohistochemical, and molecular features. There are more than 50 different types of soft tissue sarcomas including, adult fibrosarcoma, alveolar soft-part sarcoma, angiosarcoma, synovial sarcoma, undifferentiated pleomorphic sarcoma, and others.

The exact cause of most soft tissue sarcomas remains unknown, but some risk factors suffice in the development of cancers. Research establishes a direct relationship between risk factors affecting genes in cells in the soft tissues. Many family cancer syndromes have been found in which inherited DNA mutations cause a very high risk of developing breast cancer, colon, kidney, eye, or other cancers. These syndromes were noted in risk factors for Soft Tissue Sarcomas.

At present, chemotherapy regimens and targeted therapy are the two popular forms of cure in the sarcoma drugs market. Between the two, the targeted therapy is predicted to see greater uptake in the near term because of its greater efficacy. Such treatments make use of drugs or antibodies formulated from the immune system to thwart the proliferation of harmful cancer cells while leaving out the normal cells undamaged.

Soft Tissue Sarcoma Market Key Facts

  • Sarcomas are uncommon cancers that can affect any part of the body, on the inside or outside, including the muscle, bone, tendons, blood vessels, and fatty tissues. 15 people are diagnosed with sarcoma every day in the UK. That’s about 5,300 people a year.

  • According to Kumar et al., 2019, The Soft Tissue Sarcomas Incidence Rate is higher in males as compared to females.

  • The American Cancer Society’s estimates for soft tissue sarcomas in the United States for 2022 estimated that about 13,190 new soft tissue sarcomas will be diagnosed (7,590 in males and 5,600 in females).

  • About 5,130 people (2,740 males and 2,390 females) are expected to die of soft tissue sarcomas. Sarcoma survival rates have been very gradually increasing over the last two decades in the UK. Almost eight in 10 people (78%) diagnosed with sarcoma in the UK will live up to a year.

Soft Tissue Sarcoma Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Soft Tissue Sarcoma pipeline therapies. It also thoroughly assesses the Soft Tissue Sarcoma market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Soft Tissue Sarcoma drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Soft Tissue Sarcoma Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Soft Tissue Sarcoma epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Soft Tissue Sarcoma epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Soft Tissue Sarcoma Epidemiology, Segmented as –

  • Total Incident Cases of STS in the 7MM [2019-2032]

  • Type-specific Incidence of STS in the 7MM [2019-2032]

  • Age-specific Incidence of STS in the 7MM [2019-2032]

  • Stage-specific Incidence of STS in the 7MM [2019-2032]

  • Incidence of STS by Extremities (%) in the 7MM [2019-2032]

  • Gender-specific Cases of STS in the 7MM [2019-2032]

Soft Tissue Sarcoma Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Soft Tissue Sarcoma market or expected to be launched during the study period. The analysis covers the Soft Tissue Sarcoma market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Soft Tissue Sarcoma drugs based on their sale and market share.

The report also covers the Soft Tissue Sarcoma pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Soft Tissue Sarcoma companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Soft Tissue Sarcoma Market Will Evolve and Grow by 2032 @

Soft Tissue Sarcoma Therapeutics Analysis

Several major pharma and biotech companies are developing therapies for Soft Tissue Sarcoma. Currently, Advenchen Laboratories, LLC is leading the therapeutics market with its Soft Tissue Sarcoma drug candidates in the most advanced stage of clinical development.

Soft Tissue Sarcoma Companies Actively Working in the Therapeutics Market Include

Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, Moleculin Biotech, Inc., Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd., Tracon Pharmaceuticals Inc., Guangdong Xiangxue Precision Medical Technology Co., Ltd., Cornerstone Pharmaceuticals, Takara Bio Inc., Jazz Pharmaceuticals, Lyell Immunopharma, Telix Pharmaceuticals, and many others

Emerging and Marketed Soft Tissue Sarcoma Therapies Covered in the Report Include:

  • AL3818: Advenchen Laboratories

  • L19 TNF: Philogen

  • Camsirubicin: Monopar Therapeutics

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @

Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Soft Tissue Sarcoma Competitive Intelligence Analysis

4. Soft Tissue Sarcoma Market Overview at a Glance

5. Soft Tissue Sarcoma Disease Background and Overview

6. Soft Tissue Sarcoma Patient Journey

7. Soft Tissue Sarcoma Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Soft Tissue Sarcoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Soft Tissue Sarcoma Unmet Needs

10. Key Endpoints of Soft Tissue Sarcoma Treatment

11. Soft Tissue Sarcoma Marketed Therapies

12. Soft Tissue Sarcoma Emerging Drugs and Latest Therapeutic Advances

13. Soft Tissue Sarcoma Seven Major Market Analysis

14. Attribute Analysis

15. Soft Tissue Sarcoma Market Outlook (In US, EU5, and Japan)

16. Soft Tissue Sarcoma Companies Active in the Market

17. Soft Tissue Sarcoma Access and Reimbursement Overview

18. KOL Views on the Soft Tissue Sarcoma Market

19. Soft Tissue Sarcoma Market Drivers

20. Soft Tissue Sarcoma Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @



About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Other Trending Healthcare Reports by DelveInsight

Eosinophilic Esophagitis Market

“Eosinophilic Esophagitis Market Insights, Epidemiology, and Market Forecast-2032” report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the Eosinophilic Esophagitis market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Eosinophilic Esophagitis market.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States